DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Optimark (Gadoversetamide) - Published Studies


Optimark Related Published Studies

Well-designed clinical trials related to Optimark (Gadoversetamide)

Performance of delayed-enhancement magnetic resonance imaging with gadoversetamide contrast for the detection and assessment of myocardial infarction: an international, multicenter, double-blinded, randomized trial. [2008.02.05]

Well-designed clinical trials possibly related to Optimark (Gadoversetamide)

Comparison of SSFP and IR GRE techniques for measurement of total myocardial mass-influence of applied contrast dosage and implication for relative infarct size assessment. [2007]

Tissue characterization of myocardial infarction using T1rho: influence of contrast dose and time of imaging after contrast administration. [2006.11]

Other research related to Optimark (Gadoversetamide)

Pharmacokinetics of gadoversetamide injection, a gadolinium-based contrast agent, in pediatric patients. [2009.05]

Nephrogenic systemic fibrosis associated with gadoversetamide exposure: treatment with sodium thiosulfate. [2009.01]

Safety of gadoversetamide in patients with acute and chronic myocardial infarction. [2008.12]

The safety and efficacy of neuroimaging with gadoversetamide injection in pediatric patients. [2006.12]

Other possibly related research studies

Interference of gadolinium-containing contrast-enhancing agents with colorimetric calcium laboratory testing. [2005.08]

Precision, signal-to-noise ratio, and dose optimization of magnitude and phase arterial input functions in dynamic susceptibility contrast MRI. [2007.03]

Gain in signal-to-noise for first-pass contrast-enhanced abdominal MR angiography at 3 Tesla over standard 1.5 Tesla: prediction with a computer model. [2007.07]

Risk factors for developing gadolinium-induced nephrogenic systemic fibrosis. [2007.09]

Measurement of serum calcium concentration after administration of four gadolinium-based contrast agents to human volunteers. [2007.12]

[Nephrogenic systemic fibrosis as an adverse drug reaction of gadolinium-based contrast media for magnetic resonance imaging] [2007.09]

Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis. [2008.05]

Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study. [2008.06]

Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. [2008.05]

Extracellular gadolinium contrast agents: differences in stability. [2008.05]

Nephrogenic systemic fibrosis and the role of gadolinium contrast media. [2008.08]

Nephrogenic systemic fibrosis: more questions and some answers. [2008]

Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. [2008.10]

Interaction of gadolinium-based MR contrast agents with choline: implications for MR spectroscopy (MRS) of the breast. [2009.06]

Automated colorimetric gadolinium assay for verification of clearance and estimation of glomerular filtration rate. [2009.01]

Biodistribution of gadolinium-based contrast agents, including gadolinium deposition. [2009.12]

An improved microalbumin method (microALB_2) with extended analytical measurement range evaluated on the ADVIA chemistry systems. [2009]

Unusual variation of the rotator interval: insertional abnormality of the pectoralis minor tendon and absence of the coracohumeral ligament. [2010.12]

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017